Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)

Akhil Santhosh, Akash Kumar, Raja Pramanik, Ajay Gogia, Chandra Prakash Prasad, Ishaan Gupta, Nishkarsh Gupta, Winson Y Cheung, Ravindra Mohan Pandey, Atul Sharma, Atul Batra, Akhil Santhosh, Akash Kumar, Raja Pramanik, Ajay Gogia, Chandra Prakash Prasad, Ishaan Gupta, Nishkarsh Gupta, Winson Y Cheung, Ravindra Mohan Pandey, Atul Sharma, Atul Batra

Abstract

Introduction: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. Apart from oral cyclooxygenase-2 (COX-2) inhibitor (celecoxib), there are no proven strategies for the prevention of HFS. However, celecoxib is associated with significant cardiotoxicity. To date, no study has evaluated the role of topical COX inhibitor, diclofenac. In this study, we aim to compare topical 1% diclofenac gel with placebo in the prevention of capecitabine-induced HFS.

Methods: This is a randomized, placebo-controlled, double-blind, parallel-group superiority trial: the Diclofenac Topical in Reducing Capecitabine induced HFS (D-TORCH) study. A total of 264 patients with breast and gastrointestinal malignancies will be randomly allocated (stratified by sex and type of therapy [monotherapy or combination regimen with capecitabine]) to receive either 1% topical diclofenac or placebo that will be applied over the palmar and dorsal surface of the hands twice daily whilst taking capecitabine for 12 weeks. The patients will be followed up until the end of four cycles. The primary objective of this study is to compare the effect of topical diclofenac with placebo in preventing HFS (incidence of NCI CTCAEv5.0 grade 2 or higher HFS). The secondary objective is to compare the effect of topical diclofenac with placebo on preventing all grades of HFS (incidence of NCI CTCv5.0 all grade HFS), time to develop HFS (from the start of capecitabine), patient-reported outcomes (PROs) (HF-HRQoL questionnaire), adherence with the application (self-reported), capecitabine dose changes (number of patients with dose modifications due to HFS) and safety profile (NCICTCv5.0 all grade HFS) DISCUSSION: The D-TORCH study aims to determine if 1% topical diclofenac reduces the incidence of grade 2 or higher HFS in patients receiving capecitabine. To date, there have been a lot of trials for hand-foot syndrome prevention using agents like pyridoxine, vitamin E, carvedilol, and various polyherbal formulations, but none has been found successful. If the trial meets the primary end point, 1% topical diclofenac will be the new standard of care for HFS prevention.

Trial registration: Clinical Trials Registry of India CTRI/2021/01/030592 . Prospectively registered on January 19, 2021.

Keywords: Breast cancer; Capecitabine; Celecoxib; Diclofenac; Gastrointestinal cancer; Hand-foot syndrome; Prevention; Pyridoxine.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Self-reported adherence diary
Fig. 2
Fig. 2
Data collection timeline (SPIRIT figure). HFS, hand-foot syndrome; PRO, patient-reported outcome; Cox-2, cycloxygenase-2

References

    1. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23–44. doi: 10.1016/j.clinthera.2005.01.005.
    1. Jiang Z, Yang Y, Li L, Yue Z, Lan L, Pan Z. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: a meta-analysis. J Cancer Res Ther. 2018;14:S957–S963. doi: 10.4103/0973-1482.187384.
    1. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England J Med. 2017;376:2147–2159. doi: 10.1056/NEJMoa1612645.
    1. Koukourakis GV, Zacharias G, Tsalafoutas J, Theodoridis D, Kouloulias V. Capecitabine for locally advanced and metastatic colorectal cancer: a review. World J Gastrointest Oncol. 2010;2:311–321. doi: 10.4251/wjgo.v2.i8.311.
    1. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787–794. doi: 10.1016/j.jaad.2014.03.019.
    1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®) Eur J Oncol Nurs. 2004;8:S31–S40. doi: 10.1016/j.ejon.2004.06.007.
    1. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12:131–141. doi: 10.1177/1078155206069242.
    1. Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy – classification and management. JDDG. J der Deutschen Dermatologischen Gesellschaft. 2010;8:652–661.
    1. Milano G, Etienne-Grimaldi M-C, Mari M, Lassalle S, Formento J-L, Francoual M, et al. Candidate mechanisms for capecitabine-related hand–foot syndrome. Br J Clin Pharmacol. 2008;66:88–95. doi: 10.1111/j.1365-2125.2008.03159.x.
    1. Mader RM, Schrolnberger C, Rizovski B, Brunner M, Wenzel C, Locker G, et al. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer. 2003;88:782–787. doi: 10.1038/sj.bjc.6600809.
    1. Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015;125:217–243. doi: 10.1016/bs.acr.2014.10.007.
    1. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park, NY) 2002;16:31–37.
    1. Zhang R-X, Wu X-J, Lu S-X, Pan Z-Z, Wan D-S, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137:953–957. doi: 10.1007/s00432-010-0958-9.
    1. Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348–1353. doi: 10.1093/annonc/mdr400.
    1. Varga Z, Rafay Ali SS, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 9 [cited 2020 Sep 29]. Available from: .
    1. Karimi E, Gharib B, Rostami N, Navidpour L, Afshar M. Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil-associated hand-foot syndrome. J Herbal Med. 2019;17:100270. doi: 10.1016/j.hermed.2019.100270.
    1. Elif AR, Yucel KT, Ekincioglu AB, Gullu I. Capecitabine induced hand-foot syndrome: a systematic review of case reports. Clin Exper Health Sci. 2019;9(2):178–191.
    1. Da Silva DM. Rational design of topical formulations for hand-foot syndrome management. .
    1. Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. 1988;83:1198–1202. doi: 10.1080/01621459.1988.10478722.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa